View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Market Data
November 24, 2011

Pfizer to buy Excaliard Pharmaceuticals

Pfizer has entered into a definitive agreement to acquire Excaliard Pharmaceuticals, gaining access to EXC 001, a skin scarring treatment.

Pfizer has entered into a definitive agreement to acquire Excaliard Pharmaceuticals, gaining access to EXC 001, a skin scarring treatment.

Co-developed by Excaliard and Isis Pharmaceuticals, EXC 001 is an antisense oligonucleotide that will hinder the process of fibrosis.

A Phase II study of EXC 001 demonstrated positive clinical results in reducing scar severity.

Following the acquisition, Pfizer intends to continue development of EXC 001.

Pfizer will provide Excaliard an upfront payment and contingent payments.

The transaction is likely to close by the end of this year.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena